Pharmacological Treatment Strategies in Age-Related Cataracts
Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Harding, John J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1992 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Drugs & aging - Berlin [u.a.] : Springer, 1991, 2(1992), 4 vom: Juli, Seite 287-300 |
|---|---|
| Übergeordnetes Werk: |
volume:2 ; year:1992 ; number:4 ; month:07 ; pages:287-300 |
| Links: |
|---|
| DOI / URN: |
10.2165/00002512-199202040-00003 |
|---|
| Katalog-ID: |
SPR033225621 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033225621 | ||
| 003 | DE-627 | ||
| 005 | 20230519172913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1992 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00002512-199202040-00003 |2 doi | |
| 035 | |a (DE-627)SPR033225621 | ||
| 035 | |a (SPR)00002512-199202040-00003-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Harding, John J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological Treatment Strategies in Age-Related Cataracts |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. | ||
| 650 | 4 | |a Cataract |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Aldose Reductase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lens Protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sorbinil |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diabetic Cataract |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs & aging |d Berlin [u.a.] : Springer, 1991 |g 2(1992), 4 vom: Juli, Seite 287-300 |w (DE-627)327644281 |w (DE-600)2043689-0 |x 1179-1969 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:1992 |g number:4 |g month:07 |g pages:287-300 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00002512-199202040-00003 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 1992 |e 4 |c 07 |h 287-300 | ||
| author_variant |
j j h jj jjh |
|---|---|
| matchkey_str |
article:11791969:1992----::hraooiatetettaeisng |
| hierarchy_sort_str |
1992 |
| publishDate |
1992 |
| allfields |
10.2165/00002512-199202040-00003 doi (DE-627)SPR033225621 (SPR)00002512-199202040-00003-e DE-627 ger DE-627 rakwb eng 610 ASE Harding, John J. verfasserin aut Pharmacological Treatment Strategies in Age-Related Cataracts 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. Cataract (dpeaa)DE-He213 Aldose Reductase (dpeaa)DE-He213 Lens Protein (dpeaa)DE-He213 Sorbinil (dpeaa)DE-He213 Diabetic Cataract (dpeaa)DE-He213 Enthalten in Drugs & aging Berlin [u.a.] : Springer, 1991 2(1992), 4 vom: Juli, Seite 287-300 (DE-627)327644281 (DE-600)2043689-0 1179-1969 nnns volume:2 year:1992 number:4 month:07 pages:287-300 https://dx.doi.org/10.2165/00002512-199202040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 AR 2 1992 4 07 287-300 |
| spelling |
10.2165/00002512-199202040-00003 doi (DE-627)SPR033225621 (SPR)00002512-199202040-00003-e DE-627 ger DE-627 rakwb eng 610 ASE Harding, John J. verfasserin aut Pharmacological Treatment Strategies in Age-Related Cataracts 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. Cataract (dpeaa)DE-He213 Aldose Reductase (dpeaa)DE-He213 Lens Protein (dpeaa)DE-He213 Sorbinil (dpeaa)DE-He213 Diabetic Cataract (dpeaa)DE-He213 Enthalten in Drugs & aging Berlin [u.a.] : Springer, 1991 2(1992), 4 vom: Juli, Seite 287-300 (DE-627)327644281 (DE-600)2043689-0 1179-1969 nnns volume:2 year:1992 number:4 month:07 pages:287-300 https://dx.doi.org/10.2165/00002512-199202040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 AR 2 1992 4 07 287-300 |
| allfields_unstemmed |
10.2165/00002512-199202040-00003 doi (DE-627)SPR033225621 (SPR)00002512-199202040-00003-e DE-627 ger DE-627 rakwb eng 610 ASE Harding, John J. verfasserin aut Pharmacological Treatment Strategies in Age-Related Cataracts 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. Cataract (dpeaa)DE-He213 Aldose Reductase (dpeaa)DE-He213 Lens Protein (dpeaa)DE-He213 Sorbinil (dpeaa)DE-He213 Diabetic Cataract (dpeaa)DE-He213 Enthalten in Drugs & aging Berlin [u.a.] : Springer, 1991 2(1992), 4 vom: Juli, Seite 287-300 (DE-627)327644281 (DE-600)2043689-0 1179-1969 nnns volume:2 year:1992 number:4 month:07 pages:287-300 https://dx.doi.org/10.2165/00002512-199202040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 AR 2 1992 4 07 287-300 |
| allfieldsGer |
10.2165/00002512-199202040-00003 doi (DE-627)SPR033225621 (SPR)00002512-199202040-00003-e DE-627 ger DE-627 rakwb eng 610 ASE Harding, John J. verfasserin aut Pharmacological Treatment Strategies in Age-Related Cataracts 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. Cataract (dpeaa)DE-He213 Aldose Reductase (dpeaa)DE-He213 Lens Protein (dpeaa)DE-He213 Sorbinil (dpeaa)DE-He213 Diabetic Cataract (dpeaa)DE-He213 Enthalten in Drugs & aging Berlin [u.a.] : Springer, 1991 2(1992), 4 vom: Juli, Seite 287-300 (DE-627)327644281 (DE-600)2043689-0 1179-1969 nnns volume:2 year:1992 number:4 month:07 pages:287-300 https://dx.doi.org/10.2165/00002512-199202040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 AR 2 1992 4 07 287-300 |
| allfieldsSound |
10.2165/00002512-199202040-00003 doi (DE-627)SPR033225621 (SPR)00002512-199202040-00003-e DE-627 ger DE-627 rakwb eng 610 ASE Harding, John J. verfasserin aut Pharmacological Treatment Strategies in Age-Related Cataracts 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. Cataract (dpeaa)DE-He213 Aldose Reductase (dpeaa)DE-He213 Lens Protein (dpeaa)DE-He213 Sorbinil (dpeaa)DE-He213 Diabetic Cataract (dpeaa)DE-He213 Enthalten in Drugs & aging Berlin [u.a.] : Springer, 1991 2(1992), 4 vom: Juli, Seite 287-300 (DE-627)327644281 (DE-600)2043689-0 1179-1969 nnns volume:2 year:1992 number:4 month:07 pages:287-300 https://dx.doi.org/10.2165/00002512-199202040-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 AR 2 1992 4 07 287-300 |
| language |
English |
| source |
Enthalten in Drugs & aging 2(1992), 4 vom: Juli, Seite 287-300 volume:2 year:1992 number:4 month:07 pages:287-300 |
| sourceStr |
Enthalten in Drugs & aging 2(1992), 4 vom: Juli, Seite 287-300 volume:2 year:1992 number:4 month:07 pages:287-300 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Cataract Aldose Reductase Lens Protein Sorbinil Diabetic Cataract |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Drugs & aging |
| authorswithroles_txt_mv |
Harding, John J. @@aut@@ |
| publishDateDaySort_date |
1992-07-01T00:00:00Z |
| hierarchy_top_id |
327644281 |
| dewey-sort |
3610 |
| id |
SPR033225621 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033225621</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519172913.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1992 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00002512-199202040-00003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033225621</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00002512-199202040-00003-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Harding, John J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological Treatment Strategies in Age-Related Cataracts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1992</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cataract</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aldose Reductase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lens Protein</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sorbinil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetic Cataract</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs & aging</subfield><subfield code="d">Berlin [u.a.] : Springer, 1991</subfield><subfield code="g">2(1992), 4 vom: Juli, Seite 287-300</subfield><subfield code="w">(DE-627)327644281</subfield><subfield code="w">(DE-600)2043689-0</subfield><subfield code="x">1179-1969</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1992</subfield><subfield code="g">number:4</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:287-300</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00002512-199202040-00003</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1992</subfield><subfield code="e">4</subfield><subfield code="c">07</subfield><subfield code="h">287-300</subfield></datafield></record></collection>
|
| author |
Harding, John J. |
| spellingShingle |
Harding, John J. ddc 610 misc Cataract misc Aldose Reductase misc Lens Protein misc Sorbinil misc Diabetic Cataract Pharmacological Treatment Strategies in Age-Related Cataracts |
| authorStr |
Harding, John J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327644281 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-1969 |
| topic_title |
610 ASE Pharmacological Treatment Strategies in Age-Related Cataracts Cataract (dpeaa)DE-He213 Aldose Reductase (dpeaa)DE-He213 Lens Protein (dpeaa)DE-He213 Sorbinil (dpeaa)DE-He213 Diabetic Cataract (dpeaa)DE-He213 |
| topic |
ddc 610 misc Cataract misc Aldose Reductase misc Lens Protein misc Sorbinil misc Diabetic Cataract |
| topic_unstemmed |
ddc 610 misc Cataract misc Aldose Reductase misc Lens Protein misc Sorbinil misc Diabetic Cataract |
| topic_browse |
ddc 610 misc Cataract misc Aldose Reductase misc Lens Protein misc Sorbinil misc Diabetic Cataract |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Drugs & aging |
| hierarchy_parent_id |
327644281 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Drugs & aging |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327644281 (DE-600)2043689-0 |
| title |
Pharmacological Treatment Strategies in Age-Related Cataracts |
| ctrlnum |
(DE-627)SPR033225621 (SPR)00002512-199202040-00003-e |
| title_full |
Pharmacological Treatment Strategies in Age-Related Cataracts |
| author_sort |
Harding, John J. |
| journal |
Drugs & aging |
| journalStr |
Drugs & aging |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1992 |
| contenttype_str_mv |
txt |
| container_start_page |
287 |
| author_browse |
Harding, John J. |
| container_volume |
2 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Harding, John J. |
| doi_str_mv |
10.2165/00002512-199202040-00003 |
| dewey-full |
610 |
| title_sort |
pharmacological treatment strategies in age-related cataracts |
| title_auth |
Pharmacological Treatment Strategies in Age-Related Cataracts |
| abstract |
Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. |
| abstractGer |
Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. |
| abstract_unstemmed |
Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
4 |
| title_short |
Pharmacological Treatment Strategies in Age-Related Cataracts |
| url |
https://dx.doi.org/10.2165/00002512-199202040-00003 |
| remote_bool |
true |
| ppnlink |
327644281 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00002512-199202040-00003 |
| up_date |
2024-07-03T17:24:59.306Z |
| _version_ |
1803579555114385408 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033225621</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519172913.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1992 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00002512-199202040-00003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033225621</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00002512-199202040-00003-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Harding, John J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological Treatment Strategies in Age-Related Cataracts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1992</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Cataract is the major cause of blindness worldwide and at present the only approved treatment in many countries including the UK and USA is surgical removal of the lens. In other countries various anti-cataract drugs are available without proof of their efficacy. Research is continuing into the possible benefits of several groups of drugs and some vitamins. The first to be studied were sorbitol-lowering agents (aldose reductase inhibitors) based on the sorbitol hypothesis for diabetic cataract. Sorbitol-lowering agents have distinct effects in vitro and many of them delay the development of cataract in galactose-fed rats. A few delay cataract in diabetic rats but none have been proved effective in clinical trials, although these continue. Aspirin, paracetamol (acetaminophen) and ibuprofen delay diabetic cataract in rats, and have been shown to delay other experimental cataracts. Case-control studies from 3 continents indicate that these drugs, or at least aspirin, protect against cataract. Results of studies on all 3 drugs indicate a benefit even at low doses. Population-based studies did not identify any protection against early lens opacities but tiny opacities that do not impair vision are not a problem. Bendazac protects lens proteins in vitro and delays cataractogenesis in x-irradiated rats. In humans, it reached the clinical trial stage but most trials have been small and with subjective criteria of opacification. One objectively monitored trial suffered from a high drop-out rate. Other preparations studied less extensively include vitamins, aminoguanidine to prevent protein cross-linking in diabetes and agents designed to boost glutathione levels. It is probable that some agents which may delay or prevent cataract will be proved effective soon, and in the end there may be different drugs to delay cataract in different high risk groups. This is what might be expected of a multifactorial disease, although compounds that intervene in the final common pathways to cataract could have a broad efficacy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cataract</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aldose Reductase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lens Protein</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sorbinil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetic Cataract</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs & aging</subfield><subfield code="d">Berlin [u.a.] : Springer, 1991</subfield><subfield code="g">2(1992), 4 vom: Juli, Seite 287-300</subfield><subfield code="w">(DE-627)327644281</subfield><subfield code="w">(DE-600)2043689-0</subfield><subfield code="x">1179-1969</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1992</subfield><subfield code="g">number:4</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:287-300</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00002512-199202040-00003</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1992</subfield><subfield code="e">4</subfield><subfield code="c">07</subfield><subfield code="h">287-300</subfield></datafield></record></collection>
|
| score |
7.400769 |